Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials

  1. Azita H. Talasaz
  2. Parham Sadeghipour
  3. Maryam Aghakouchakzadeh
  4. Isaac Dreyfus
  5. Hessam Kakavand
  6. Hamid Ariannejad
  7. Aakriti Gupta
  8. Mahesh V. Madhavan
  9. Benjamin W. Van Tassell
  10. David Jimenez
  11. Manuel Monreal
  12. Muthiah Vaduganathan
  13. John Fanikos
  14. Dave L Dixon
  15. Gregory Piazza
  16. Sahil A. Parikh
  17. Deepak L. Bhatt
  18. Gregory YH Lip
  19. Gregg W. Stone
  20. Harlan M. Krumholz
  21. Peter Libby
  22. Samuel Z. Goldhaber
  23. Behnood Bikdeli
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Coronavirus disease 2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multi-organ manifestations. Lipid modulating agents may be useful in treating patients with COVID-19. They may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglycerides portends worse outcome in patients with COVID-19. Upon a systematic search, 40 RCTs with lipid modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrates RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for management or prevention of COVID-19. This manuscript summarizes the ongoing or completed randomized controlled trials (RCTs) of lipid modulating agents in COVID-19 and the implications of these trials for patient management.

Related articles

Related articles are currently not available for this article.